BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
12.31
+0.13 (1.07%)
Nov 28, 2025, 4:00 PM EST - Market closed

BBOT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Sep '25 Dec '24 Dec '23
Selling, General & Admin
21.637.768.49
Research & Development
102.6773.1156.29
Operating Expenses
124.2980.8664.77
Operating Income
-124.29-80.86-64.77
Interest & Investment Income
9.056.380.07
Other Non Operating Income (Expenses)
0.30.21-
Pretax Income
-114.93-74.28-64.7
Net Income
-114.93-74.28-64.7
Net Income to Common
-114.93-74.28-64.7
Shares Outstanding (Basic)
1100
Shares Outstanding (Diluted)
1100
Shares Change (YoY)
8840.04%16.36%-
EPS (Basic)
-10.31-511.80-518.73
EPS (Diluted)
-10.31-511.80-518.73
Free Cash Flow
-87.24-55.08-52.49
Free Cash Flow Per Share
-7.82-379.51-420.87
EBITDA
-124.04-80.66-64.68
D&A For EBITDA
0.250.210.09
EBIT
-124.29-80.86-64.77
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.